Q3 2021 Financial Presentation2021-11-04 The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 StudyQuarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 StudyAnnual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May
